An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease [0.03%]
基于证据的塔拉格鲁卡塞α治疗戈谢病患者的潜在疗效和安全性的综述性评价
Carla Em Hollak
Carla Em Hollak
Gaucher disease is an inherited lysosomal storage disorder, characterized by deficient activity of glucocerebrosidase leading to storage of glucocerebroside in tissue macrophages. Type I disease, the most prevalent form, lacks central nervo...
Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation [0.03%]
达非林治疗早泄有效性的循证评价
Ej McCarty,Ww Dinsmore
Ej McCarty
Premature ejaculation (PE) is a major issue in male sexual health. The global prevalence of PE is estimated to be between 20% and 40%, making it the most common sexual dysfunction in men. PE causes distress and reduced quality of life for p...
Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes [0.03%]
利西那肽：用於治療二型糖尿病的潛力證據分析
Anthony H Barnett
Anthony H Barnett
Lixisenatide is a once-daily glucagon-like peptide 1 (GLP-1) receptor agonist mimicking several favorable actions of endogenous GLP-1 that result in improved glycemic control with little or no hypoglycemia and weight loss. Phase II trials h...
Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review [0.03%]
阿zeptanol（吸入溶液）治疗囊性纤维化患者的慢性肺部感染：基于证据的评估报告
Stephen Kirkby,Kimberly Novak,Karen McCoy
Stephen Kirkby
Cystic fibrosis (CF) is a genetic disease caused by abnormal chloride transport across cellular membranes. In the respiratory tract, this molecular defect causes obstruction of the airways by mucus and chronic endobronchial infection. The m...
Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma [0.03%]
卡非佐米在复发及难治性淋巴瘤和多发性骨髓瘤治疗中的作用不容忽视
Salvia Jain,Catherine Diefenbach,Jasmine Zain et al.
Salvia Jain et al.
Proteasome inhibition forms the cornerstone of antimyeloma therapy. The first-in-class proteasome inhibitor, bortezomib, either alone or in combination with other chemotherapeutic agents, induces high overall response rates and response qua...
Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis [0.03%]
达拉弗马吡啶缓释制剂改善多发性硬化症患者步行速度的临床疗效研究
Douglas R Jeffery,Emily Poole Pharr
Douglas R Jeffery
Dalfampridine sustained-release (SR) is a time-release formulation of 4-aminopyridine, recently approved by the Food and Drug Administration to improve walking in patients with multiple sclerosis (MS). In Phase II trials, walking speed and ...
Pitavastatin: evidence for its place in treatment of hypercholesterolemia [0.03%]
匹伐他汀：用于治疗高胆固醇的证据及其疗效分析
Peter Alagona Jr
Peter Alagona Jr
Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, are the most potent pharmacologic agents for lowering total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). They have become an accepted standard of c...
Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes [0.03%]
替卡格雷作为口服抗血小板药物治疗急性冠脉综合征患者以减少主要心血管事件的临床潜力证据评估
Bernardo Lombo,José G Díez
Bernardo Lombo
Introduction: Ticagrelor, the first direct-acting, reversibly binding oral P2Y12 receptor antagonist, appears to have a favorable efficacy and safety profile. ...
Huda Salman,Hillard M Lazarus
Huda Salman
High-dose chemotherapy and autologous transplantation of hematopoietic cells is a crucial treatment option for hematologic malignancy patients. Current mobilization regimes often do not provide adequate numbers of CD34(+) cells. The chemoki...
Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosis [0.03%]
基于证据的芬戈莫德治疗复发性多发性硬化的潜在应用评估
Emilio Portaccio
Emilio Portaccio
Multiple sclerosis is an autoimmune inflammatory demyelinating disease of the central nervous system and represents one of the most common causes of chronic neurologic disability in young adults. All the current disease-modifying drugs are ...